FDA Approves 2nd Biosimilar for J&J's Remicade

The U.S. FDA approved Inflectra (infliximab-dyyb) for multiple indications, and it is administered by intravenous infusion. This is the second biosimilar approved by the FDA.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news